

Glatiramer Acetate (Copaxone, Glatopa)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Glatiramer Acetate (Copaxone, Glatopa)	1
Summary	1
Definitions	2
Clinical Indications	4
Medical Necessity Criteria for Clinical Review	4
General Medical Necessity Criteria	4
Medical Necessity Criteria for Initial Clinical Review	4
Initial Indication-Specific Criteria	4
Multiple Sclerosis - Adults	4
Medical Necessity Criteria for Subsequent Clinical Review	5
Subsequent Indication-Specific Criteria	5
Multiple Sclerosis - Adults	5
Experimental or Investigational / Not Medically Necessary[s]	5
References	6
Clinical Guideline Revision / History Information	8

Summary

Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system. It typically presents in young adults (generally diagnosed before 50 years of age) with symptoms such as vision problems, muscle weakness, numbness, and difficulty with balance and coordination. The most common form is relapsing-remitting MS (occurring in about 85% of patients), characterized by acute attacks followed by periods of remission. Treatment goals include reducing relapses, slowing disability progression, and managing symptoms. Disease-modifying therapies are the primary treatment approach and include injectable medications (e.g., interferons, glatiramer acetate), oral medications (e.g., dimethyl fumarate, fingolimod, teriflunomide, etc.), and infusion therapies (e.g., natalizumab, ocrelizumab).

MS is a progressive disease, meaning that symptoms tend to worsen over time, and it can be classified into several types, including relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS).

Currently, there is no cure for MS, but various treatment options are available to manage symptoms, slow the progression of the disease, and improve quality of life.

- Disease-modifying therapies (DMTs) are a class of medications that target the immune system to reduce inflammation and slow down the progression of the disease. The type of DMT prescribed will depend on the type and severity of MS, as well as the individual's medical history and preferences. Some common DMTs include interferon beta, glatiramer acetate, dimethyl fumarate, and fingolimod.
- High dose corticosteroids, such as high dose intravenous methylprednisolone or oral prednisone can be prescribed to reduce inflammation during acute MS relapses.
- Symptomatic treatments are also available to manage specific symptoms of MS, such as muscle spasms, bladder problems, and depression. Physical therapy, occupational therapy, and speech therapy can help individuals with MS maintain mobility, independence, and communication skills.

Glatiramer acetate is a medication prescribed for adults with various relapsing forms of multiple sclerosis (MS). These forms include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. Clinical studies have demonstrated that glatiramer acetate can decrease the frequency of relapses in patients with relapsing-remitting MS. Additionally, for individuals who have experienced a single clinical episode and show MRI findings suggestive of MS, this drug has been found to lower the likelihood of the condition progressing to definitive MS. Glatiramer acetate is administered subcutaneously (SUBQ) using a prefilled syringe or a compatible injection device.

Definitions

"Clinically isolated syndrome" refers to a first episode of neurologic symptoms lasting at least 24 hours caused by inflammation or demyelination in the central nervous system.

"Compendia" are summaries of drug information and medical evidence to support decision-making about the appropriate use of drugs and medical procedures. Examples include, but are not limited to:

1. American Hospital Formulary Service Drug Information
2. Clinical pharmacology
3. National Comprehensive Cancer Network Drugs and Biologics Compendium
4. Thomson Micromedex DrugDex
5. United States Pharmacopeia-National Formulary (USP-NF)

"Disease-modifying therapy" is a medication that modifies the course of MS by reducing relapses and slowing disability progression.

"Documentation" refers to written information, including but not limited to:

- Up-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses; or

Prescription claims records, and/or prescription receipts to support prior trials of formulary alternatives. "MRI" or "Magnetic Resonance Imaging" refers to a medical imaging technique that creates detailed three-dimensional (3D) images of the organs and tissues in your body. A brain MRI can reveal areas of active MS disease called lesions within the central nervous system.

"Multiple sclerosis" is a chronic autoimmune disease of the central nervous system characterized by inflammation, demyelination, and neurodegeneration.

"Primary progressive MS" refers to worsening neurologic function from the onset of symptoms, without early relapses or remissions.

"Relapse" is defined as the appearance of new symptoms or the worsening of existing symptoms lasting at least 24 hours in the absence of fever or infection.

"Relapsing-remitting MS" refers to a disease course characterized by clearly defined attacks of new or increasing neurologic symptoms followed by periods of partial or complete recovery.

"[s]" indicates state mandates may apply.

"Secondary progressive MS" is a disease course following relapsing-remitting MS that is characterized by a progressive worsening of neurologic function over time with or without relapses.

Clinical Indications

Medical Necessity Criteria for Clinical Review

General Medical Necessity Criteria

The Plan considers Glatiramer Acetate (Copaxone, Glatopa) medically necessary when ONE of the following criteria are met:

1. Authorization may be granted for pediatric members less than 18 years of age with multiple sclerosis when there is documentation that the benefits outweigh the risks; *OR*
Note: If approved, the requested product will be authorized for up until the member reaches 18 years of age.
2. The member meets the applicable [Medical Necessity Criteria for Initial Clinical Review](#) or [Subsequent Clinical Review](#) listed below.

Medical Necessity Criteria for Initial Clinical Review

Initial Indication-Specific Criteria

Multiple Sclerosis - Adults

The Plan considers Glatiramer Acetate (Copaxone, Glatopa) when recent (within the last 3 months) clinical chart documentation provided indicates the member meets ALL of the following:

1. The medication is prescribed by or in consultation with a neurologist or physician who specializes in the treatment of multiple sclerosis; *AND*
2. Is 18 years of age or older; *AND*
3. Has ONE (1) of the following forms of multiple sclerosis:
 - a. Relapsing-remitting (RRMS); *or*
 - b. Active secondary progressive disease (SPMS); *or*
 - c. Clinically isolated syndrome (CIS); *AND*
4. For glatiramer products (i.e., glatiramer acetate, brand Glatopa [glatiramer acetate]) - the member is unable to use, or has tried and failed Copaxone (glatiramer acetate),^[5] *AND*
5. Glatiramer Acetate will be used as monotherapy for multiple sclerosis (i.e., member is not using and will not use other disease-modifying MS therapies while on glatiramer acetate [Copaxone, Glatopa]); *AND*
6. Glatiramer acetate is being prescribed within the manufacturer's published dosing guidelines or falls within dosing guidelines found in a compendia of current literature.
 - o *The recommended dose is either:*
 - i. 20 mg/mL administered subcutaneously once daily; *or*
 1. 20 mg/mL: 30 syringes per 30 days
 - ii. 40 mg/mL administered subcutaneously three times per week at least 48 hours apart.
 1. 40 mg/mL: 12 syringes per 28 days

If the above prior authorization criteria are met, the requested product will be authorized for up to 12-months.^[s]

Continued Care

Medical Necessity Criteria for Subsequent Clinical Review

Subsequent Indication-Specific Criteria

Multiple Sclerosis - Adults

The Plan considers Glatiramer Acetate (Copaxone, Glatopa) when recent (within the last 6 months) clinical chart documentation provided indicates the member meets BOTH of the following:

1. The requested medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis; *AND*
2. The member has experienced at least ONE (1) of the following:
 - a. Improvement in at least ONE (1) objective measure, such as:
 - i. Reduced disease activity on MRI; *and/or*
 - ii. Improved or stable disability scores; *and/or*
 - iii. Reduced relapse rate; *and/or*
 - iv. Improved fatigue or walking assessments; *AND/OR*
 - b. The member has shown stabilization or improvement in at least ONE (1) MS symptom, such as:
 - i. Motor function; *and/or*
 - ii. Fatigue; *and/or*
 - iii. Vision; *and/or*
 - iv. Bowel/bladder function; *and/or*
 - v. Spasticity; *and/or*
 - vi. Walking/gait; *and/or*
 - vii. Pain/numbness/tingling.

If the above reauthorization criteria are met, the requested product will be authorized for up to 12-months.^[s]

Experimental or Investigational / Not Medically Necessary^[s]

Glatiramer Acetate (Copaxone, Glatopa) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, unproven, or not medically necessary. Non-covered indications include, but are not limited to, the following:

- Use for the treatment of primary progressive multiple sclerosis (PPMS). In a randomized controlled trial with 934 participants with PPMS, there was no significant difference between glatiramer acetate (Copaxone, Glatopa) than placebo in delay time to sustained accumulated

disability (HR 0.87, 95% CI 0.71-1.07, p=0.1753). Power was reduced by the lower than expected event rate and higher than expected drop-out rate. There are no other studies to support the safety and efficacy of glatiramer acetate (Copaxone, Glatopa) for the management of PPMS.

- Use in combination with other disease-modifying therapies for multiple sclerosis.
- Use for indications other than FDA-approved relapsing forms of multiple sclerosis.

References

1. Bainbridge JL, Miravalle A, Wong PS. Multiple Sclerosis. In DiPiro JT, Yee GC, Posey LM, et al, eds. *Pharmacotherapy: A Pathophysiologic Approach*. 11th ed. New York, NY: McGraw-Hill; 2019.
2. Benallegue N, Rollot F, Wiertelowski S, Casey R, Debouverie M, Kerbrat A, De Seze J, Ciron J, Ruet A, Labauge P, Maillart E, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Heinzlef O, Pelletier J, Thouvenot E, Al Khedr A, Bourre B, Casez O, Cabre P, Wahab A, Magy L, Vukusic S, Laplaud DA; OFSEP (Observatoire Français de la Sclérose en Plaques) Investigators. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis. *JAMA Neurol*. 2024 Mar 1;81(3):273-282.
3. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-relapsing multiple sclerosis. *N Engl J Med*. 1987;317(7):408-414. doi:10.1056/NEJM198708133170703.
4. Chitnis T, Tenenbaum S, Banwell B, Krupp L, Pohl D, Rostasy K, Yeh EA, Bykova O, Wassmer E, Tardieu M, Kornberg A, Ghezzi A; International Pediatric Multiple Sclerosis Study Group. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. *Mult Scler*. 2012 Jan;18(1):116-27.
5. Comi G, Filippi M, Wolinsky JS; and the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. *Ann Neurol*. 2001;49(3):290-297. <https://doi.org/10.1002/ana.64>
6. Comi G, Martinelli V, Rodegher M, et al., Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2009 Oct 31;374(9700):1503-11. doi: 10.1016/S0140-6736(09)61259-9. Epub 2009 Oct 6. Erratum in: *Lancet*. 2010 Apr 24;375(9724):1436.
7. Copaxone (glatiramer acetate) [prescribing information]. Parsippany, NJ: Teva Neuroscience Inc; November 2023.
8. Ford CC, Cohen JA, Goodman AD, et al., Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study. *Mult Scler*. 2022 Oct;28(11):1729-1743. doi: 10.1177/13524585221094239. Epub 2022 Jun 29.
9. Glatopa (glatiramer acetate) [prescribing information]. Princeton, NJ: Sandoz Inc; March 2023.
10. Hauser, S., & Cree, B. (2020). Treatment of Multiple Sclerosis: A Review.. *The American journal of medicine*. <https://doi.org/10.1016/j.amjmed.2020.05.049>.
11. He A, Merkel B, Brown JW, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. *Lancet Neurol*. 2020 Apr;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18.
12. Johnson KP, Brooks BR, Cohen JA, et al., Copolymer 1 reduces relapse rate and improves disability in relapsing-relapsing multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. *Neurology*. 1995 Jul;45(7):1268-76. doi: 10.1212/wnl.45.7.1268.
13. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R; GALA Study Group. Three times weekly glatiramer acetate in relapsing-relapsing multiple sclerosis. *Ann Neurol*. 2013 Jun;73(6):705-13. doi: 10.1002/ana.23938. Epub 2013 Jun 28.

14. Krysko KM, Graves JS, Rensel M, et al; US Network of Pediatric MS Centers. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. *Ann Neurol*. 2020 Jul;88(1):42-55.
15. Krysko KM, Graves J, Rensel M, et al; US Network of Pediatric MS Centers. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. *Neurology*. 2018 Nov 6;91(19):e1778-e1787.
16. Li H, Hu F, Zhang Y, Li K. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. *J Neurol*. 2020 Dec;267(12):3489-3498. doi: 10.1007/s00415-019-09395-w. Epub 2019 May 25.
17. Luzzio C, Dangond F. Multiple Sclerosis Guidelines. MedScape. 12 March 2024. Available at: <https://emedicine.medscape.com/article/1146199-guidelines#g1>. Accessed 20 January 2026.
18. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. *JAMA*. 2021;325(8):765-779. doi:10.1001/jama.2020.26858
19. Montalban X et al:ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. *Eur J Neurol*. 25(2):215-37, 2018
20. Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. *Lancet Neurol*. 2025 Oct;24(10):850-865. doi: 10.1016/S1474-4422(25)00270-4. Erratum in: *Lancet Neurol*. 2025 Nov;24(11):e13. doi: 10.1016/S1474-4422(25)00355-2.
21. Multiple Sclerosis Society of Canada. Disease-modifying therapies. <https://mssociety.ca/managing-ms/treatments/medications/disease-modifying-therapies-dmts>.
22. National Institute for Health and Care Excellence [NICE]. Multiple sclerosis in adults: management. NICE Guidelines [NG220]. 22 June 2022. Available at: <https://www.nice.org.uk/guidance/ng220/chapter/Recommendations#ms-symptom-management-and-rehabilitation>. Accessed 20 January 2026.
23. National MS Society. Disease-modifying therapies for MS (updated March 2022). Available from National MS Society website: <https://nms2cdn.azureedge.net/cmssite/nationalmssociety/media/msnationalfiles/brochures/brochure-the-ms-disease-modifying-medications.pdf>.
24. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018;90(17):777-788.
25. Rashid W, Ciccarelli O, Leary SM, et al. Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance. *Pract Neurol*. 2025 Jan 16;25(1):18-24. doi: 10.1136/pn-2024-004228.
26. Reich DS, Lucchinetti CF, Calabresi PA. 2018. Multiple sclerosis. *New England Journal of Medicine* 378(2):169-180
27. Simone M, Palumbi R, Achille M, et al. A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis. *Neurol Sci*. 2025 Oct;46(10):5391-5400. doi: 10.1007/s10072-025-08377-3. Epub 2025 Aug 8.
28. Sladowska K, Mocko P, Brzostek T, et al. Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies. *Mult Scler Relat Disord*. 2025. doi: 10.1016/j.msard.2025.106263
29. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence summary. Multiple Sclerosis Coalition. Available from the National MS Society Website: <https://www.nationalmssociety.org/>.
30. Tramacere I, Del Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. *Cochrane Database Syst Rev* 2015;9:CD011381.
31. Walsh R, Chitnis T. Therapeutic Advances in Pediatric Multiple Sclerosis. *Children*. 2025;12(3):259.

32. Wang X, Zhao M, Liu P, Shang X. Effectiveness of combination therapy versus monotherapy in multiple sclerosis: A systematic review and meta-analysis. *Pak J Pharm Sci.* 2025 Jul-Aug;38(4):1334-1346. doi: 10.36721/PJPS.2025.38.4.REG.14387.1.
33. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. *Ann Neurol.* 2007 Jan;61(1):14-24. doi: 10.1002/ana.21079.
34. Yang, J., Rempe, T., Whitmire, N., Dunn-Pirio, A., & Graves, J. (2022). Therapeutic Advances in Multiple Sclerosis. *Frontiers in Neurology*, 13. <https://doi.org/10.3389/fneur.2022.824926>.

Clinical Guideline Revision / History Information

Original Date: 06/27/2024

Reviewed/Revised: 12/19/2024, 10/01/2025, 05/01/2026